Belleville Community Blood Drive
Share
Tweet
The Belleville community is proud to partner with the American Red Cross for the Missing Types campaign to increase blood donations and encourage individuals to make an appointment to give blood this summer.
Belleville will join the Red Cross and other companies, organizations, brands and individuals to remove the letters A, B and O – the letters that make up the main blood groups – from its logo and public-facing messaging on June 25th. When those letters disappear, you notice. And when A, B, O and AB blood types are missing from hospital shelves, patient care may be impacted.
“The Belleville community knows having a stable and sufficient blood supply is critical to our community,” said Diane Nichols, Account Manager with American Red Cross. “Learning only three out of every 100 people donate blood motivated us to partner with the Red Cross on the Missing Types campaign. Hopefully, we can help inspire more people to make an appointment and donate within the next few weeks.”
The Belleville Community Blood Drive will be held on Tuesday, June 25, 2019, from 1:00 p.m. to 6:00 p.m., at St. Mary of Lourdes, 221 Frederick Street.
Join the Movement
New and current donors can do their important part to help fill in the missing types and ensure blood is available for patients in need. Visit RedCrossBlood.org/MissingTypes, download the Red Cross Blood Donor App or call 1-800-RED CROSS (1-800-733-2767) to schedule an appointment to give.
Summer is one of the most challenging times of the year for the Red Cross to collect blood and platelet donations, with schools that host blood drives on break and many people enjoying vacation and other seasonal activities. Yet patients don’t get a vacation from needing lifesaving blood during the summer months. Every two seconds, someone in the United States needs blood, and it can only come from volunteer donors. Blood and platelets are needed for accident and burn victims, heart surgery and organ transplant patients, and those receiving treatment for leukemia, cancer or sickle cell disease.